Regeneron Pharmaceuticals (REGN) Assets (2009 - 2026)

Regeneron Pharmaceuticals has reported Assets for 18 years, with the latest figure at $40.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 8.85% year-over-year to $40.9 billion; the trailing twelve-month figure through Mar 2026 stood at $40.9 billion (up 8.85% YoY), and the FY2025 full-year result was $40.6 billion, up 7.41% from the prior year.
• Assets for Q1 2026 stood at $40.9 billion, up from $40.6 billion in the prior quarter.
• The five-year high for Assets was $40.9 billion in Q1 2026, with the low at $26.3 billion in Q1 2022.
• Average Assets over 5 years is $34.1 billion, with a median of $34.4 billion recorded in 2024.
• Year-over-year, Assets jumped 48.26% in 2022 and rose 5.91% in 2025.
• Tracing REGN's Assets over 5 years: stood at $29.2 billion in 2022, then climbed by 13.23% to $33.1 billion in 2023, then advanced by 14.15% to $37.8 billion in 2024, then grew by 7.41% to $40.6 billion in 2025, then advanced by 0.76% to $40.9 billion in 2026.
• The last three Assets figures came in at $40.9 billion (Q1 2026), $40.6 billion (Q4 2025), and $40.2 billion (Q3 2025), per Business Quant data.

Peer Comparison